As of December 31, 2023, cash and cash equivalents were $121.5 million, excluding the $95.0 million gross proceeds expected to be raised in the private placement announced today. Lexeo expects the additional funds raised in the financing to extend its runway into 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LXEO:
- Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
- 3 Best Stocks to Buy Now, 2/12/2024, According to Top Analysts
- Lexeo Therapeutics Bolsters Leadership with Key Hires
- Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments